Doxycycline (Vibramycin, Doryx, Oracea, Monodox)
Other Medications · Approved since 1967
Description
Doxycycline is a tetracycline antibiotic that serves as a supportive care medication in colorectal cancer treatment, specifically used to prevent and manage severe skin toxicity associated with anti-EGFR therapies like cetuximab. This broad-spectrum antibiotic is employed prophylactically to reduce the incidence and severity of acneiform rash, a common dose-limiting side effect of EGFR inhibitors. Doxycycline's anti-inflammatory properties, in addition to its antimicrobial effects, help mitigate the skin reactions that can compromise patient quality of life and treatment compliance.
Mechanism of Action
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the ribosome. Beyond its antimicrobial action, doxycycline possesses anti-inflammatory properties through inhibition of matrix metalloproteinases and reduction of inflammatory cytokine production, which helps control the inflammatory component of EGFR inhibitor-induced skin toxicity.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Vibramycin, Doryx, Oracea, Monodox |
| Category | Other Medications |
 Status | Off-label |
| Administration | Oral |
| Year Approved | 1967 |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.